Gilead Beats Antitrust Suit Over HIV Drug Patents

By John Kennedy (July 6, 2016, 9:32 PM EDT) -- AIDS Healthcare Foundation Inc. can't invalidate five patents for HIV treatments or support antitrust claims against Gilead Sciences Inc., a California federal judge said Wednesday as he dismissed the case in its entirety.

U.S. District Judge William Alsup said that the foundation had not proven a controversy surrounding the patents, which cover tenofovir alafenamide fumarate, or TAF — a type of HIV treatment that is safer and more efficient than its precursor, tenofovir disoproxil fumarate, or TDF — and had not supported its Sherman Act, Cartwright Act or state law antitrust claims.

The organization has claimed that Gilead gamed the U.S. Food and...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!